Labiotech.eu

Eligo Bioscience Microbiome CRISPR Bacteriophage

News and Trends 26 Sep 2017

French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots

Eligo Bioscience has announced its first fundraising round, amassing $20M (€18.5M) that will be put towards bringing it CRISPR nanobots to a first clinical trial in humans. The French startup Eligo Bioscience has grown rapidly since its foundation in 2014. The company has announced today its Series A round, which, led by Khosla Ventures and […]

September 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Sep 2017

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix mRNA cancer therapies. eTheRNA has been awarded the €1M industrial R&D projects grant by Flanders Innovation and Entrepreneurship. The company’s technology uses mRNA that stimulates the immune system to effectively treat cancer, giving rise to long-lasting remission in patients. It will […]

September 25, 2017 - 1 minutemin - By Alex Dale

News and Trends 25 Sep 2017

Sanofi ‘Super-Antibody’ HIV Treatment Kills the Majority of Virus Strains

Sanofi, in collaboration with the US National Institute of Health, is developing an antibody HIV treatment that can kill 99% of strains. Human immunodeficiency virus (HIV) is notoriously difficult to treat as it mutates so quickly. Some patients develop ‘broadly neutralizing antibodies’ that attack fundamental parts of the virus, and are therefore very powerful tools. Researchers […]

September 25, 2017 - 3 minutesmins - By Alex Dale

Interview 25 Sep 2017

Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model

Onno van de Stolpe founded Galapagos nearly 20 years ago and still is CEO of this European biotech success story. I caught up with him for the full story. It was when he was studying at the agricultural university in Wageningen, The Netherlands, when “I got fascinated by molecular biology, and the biotech industry in […]

September 25, 2017 - 10 minutesmins - By Evelyn Warner

Anna Dumitriu Bioart and Bacteria Oxford

News and Trends 23 Sep 2017

BioArt and Bacteria Exhibition is Coming to Oxford

A new exhibition in Oxford features the beautiful art of Anna Dumitriu, exploring the complex world of microbes and how we interact with them. Anna Dumitriu, prolific bioartist that works with bacteria, will show some of her best work at the solo exhibition BioArt and Bacteria that will be hosted at the Museum of the […]

September 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Sep 2017

EU gives French Biotech €20M to Continue the Fight Against Antibiotic Resistance

Da Volterra has been boosted by a €20M loan to speed up the development of solutions for the antibiotic resistance crisis. The French biopharma concentrates on the prevention and treatment of serious infections. This is a big area of interest due to rapidly rising antibiotic resistance. The company has been boosted by a €20M loan from the […]

September 22, 2017 - 3 minutesmins - By Alex Dale

helloscience novozymes water scarcity3 1

News and Trends 21 Sep 2017

Novozymes Launches HelloScience to Encourage Global Collaboration on Big Issues

The HelloScience platform will provide an online network where solutions for the world’s biggest challenges can be developed. First up, water scarcity. Novozyme’s new online network, HelloScience, will provide a space for innovators, start-ups, companies, and others to come together and work on developing solutions for some of the world’s biggest challenges. One of the […]

September 21, 2017 - 2 minutesmins - By Alex Dale

News and Trends 21 Sep 2017

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

Merck and Pfizer’s new immunotherapy, avelumab, has been approved by the European Commission to treat metastatic Merkel cell carcinoma, an aggressive form of skin cancer. The approval is based on data from a Phase II study, JAVELIN Merkel 200, where subjects responded well to treatment for a sustained period of time. Earlier this year, Avelumab was […]

September 21, 2017 - 3 minutesmins - By Alex Dale

Inside Labiotech 21 Sep 2017

How we raised our second financing round? (Yes, it was tough)

You might have seen our press release or read about it on other media outlets, such as Tech.eu, EU-Startups, Gruenderszene.de, VC-Magazin, Deutsche-startups.de or Wan-Ifra: we just raised our second financing round. It’s a major milestone for the development of Labiotech.eu as it will allow us to continue investing in amazing content, launch new products and […]

September 21, 2017 - 6 minutesmins - By Philip Hemme

More News! 20 Sep 2017

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work on a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets, on which Glythera will have the option […]

September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Sep 2017

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

The FDA has backed Kiadis Pharma’s lead blood cancer product by granting it the Regenerative Medicine Advanced Therapy designation. Kiadis Pharma, based in Amsterdam, develops products to make bone marrow transplants for the treatment of blood cancer and inherited blood disorders safer and more effective. Their lead T cell immunotherapy candidate, ATIR101, reduces the risk of complications, and […]

September 20, 2017 - 2 minutesmins - By Alex Dale

biotech portugal vesalius biocapital fund

News and Trends 20 Sep 2017

Biotech in Portugal gets a Boost with New Investment Fund

Vesalius Biocapital and the Portuguese National Promotional Bank have announced a new joint venture that will invest in late-stage healthcare companies. The Instituição Financeira de Desenvolvimento (IFD), or Portuguese National Promotional Bank, is launching its first joint investment with an international VC, Vesalius Biocapital. Though its size hasn’t been revealed yet, the new fund is a 50/50 venture […]

September 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

Sanofi ‘Super-Antibody’ HIV Treatment Kills the Majority of Virus Strains

Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model

BioArt and Bacteria Exhibition is Coming to Oxford

EU gives French Biotech €20M to Continue the Fight Against Antibiotic Resistance

Novozymes Launches HelloScience to Encourage Global Collaboration on Big Issues

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

How we raised our second financing round? (Yes, it was tough)

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

Biotech in Portugal gets a Boost with New Investment Fund

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!